Penumbra (PEN) Shareholder's Equity Growth (1y) (2015 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Abbott Laboratories | 152.82 Bn | 146.17 Bn | 6.27 Bn |
| 2 | Stryker | 115.07 Bn | 112.19 Bn | 3.81 Bn |
| 3 | Medtronic | 95.25 Bn | 87.08 Bn | 5.76 Bn |
| 4 | Boston Scientific | 71.38 Bn | 70.17 Bn | 3.61 Bn |
| 5 | Edwards Lifesciences | 51.08 Bn | 47.41 Bn | 1.29 Bn |
| 6 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn |
| 7 | Dexcom | 28.84 Bn | 27.72 Bn | 750.30 Mn |
| 8 | GE HealthCare Technologies | 28.56 Bn | 26.49 Bn | 1.98 Bn |
| 9 | Steris | 20.71 Bn | 20.30 Bn | 697.10 Mn |
| 10 | Penumbra | 12.52 Bn | 11.91 Bn | 253.41 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 21.51% |
| Dec 31, 2025 | 24.04% |
| Sep 30, 2025 | 23.04% |
| Jun 30, 2025 | 11.43% |
| Mar 31, 2025 | 0.78% |
| Dec 31, 2024 | -2.38% |
| Sep 30, 2024 | 0.01% |
| Jun 30, 2024 | 8.88% |
| Mar 31, 2024 | 17.48% |
| Dec 31, 2023 | 18.03% |
| Sep 30, 2023 | 13.39% |
| Jun 30, 2023 | 9.95% |
| Mar 31, 2023 | 6.79% |
| Dec 31, 2022 | 4.71% |
| Sep 30, 2022 | 42.24% |
| Jun 30, 2022 | 44.05% |
| Mar 31, 2022 | 47.48% |
| Dec 31, 2021 | 49.57% |
| Sep 30, 2021 | 10.47% |
| Jun 30, 2021 | 8.06% |
| Mar 31, 2021 | 33.26% |
| Dec 31, 2020 | 31.34% |
| Sep 30, 2020 | 32.72% |
| Jun 30, 2020 | 37.20% |
| Mar 31, 2020 | 11.78% |
| Dec 31, 2019 | 14.96% |
| Sep 30, 2019 | 14.09% |
| Jun 30, 2019 | 6.82% |
| Mar 31, 2019 | 5.24% |
| Dec 31, 2018 | 5.50% |
| Sep 30, 2018 | 2,557,950.00% |
| Jun 30, 2018 | 1,119,044.74% |
| Mar 31, 2018 | 1,185,588.57% |
| Dec 31, 2017 | 50.22% |
| Sep 30, 2017 | -82.42% |
| Jun 30, 2017 | -118.45% |
| Mar 31, 2017 | 95.55% |
| Dec 31, 2016 | 14.63% |
| Sep 30, 2016 | 105.92% |
| Jun 30, 2016 | 116.71% |
| Mar 31, 2016 | 55.16% |
| Dec 31, 2015 | 1,979.73% |